SCHEMBL133891

SCHEMBL133891

Cc1ccc(C(=O)c2c(N)sc3c2CC(C)C3)cc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.58
ALDH1A1 P00352 9/20 0.58
LMNA P02545 4/20 0.58
NPC1 O15118 1/20 0.58
HTT P42858 1/20 0.58
RAB9A P51151 1/20 0.58
HPGD P15428 4/20 0.48
KDM4E B2RXH2 3/20 0.48
ALOX15 P16050 2/20 0.48
HSD17B10 Q99714 2/20 0.48
TDP1 Q9NUW8 1/20 0.46
GAA P10253 3/20 0.45
TSHR P16473 1/20 0.45
ALOX12 P18054 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ADORA1 P30542 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL133029 0.77 TDP1 (0.70) MAPTALDH1A1LMNAHPGDKDM4E
SCHEMBL136844 0.77 TDP1 (0.74) MAPTALDH1A1LMNAHPGDKDM4E
SCHEMBL135846 0.76 TDP1 (0.72) MAPTALDH1A1LMNAHPGDKDM4E
SCHEMBL14195744 0.76 MAPT (0.65) MAPTALDH1A1LMNANPC1HTT
SCHEMBL138626 0.74 ALDH1A1 (0.48) MAPTALDH1A1LMNANPC1HTT
SCHEMBL135906 0.73 TDP1 (0.50) MAPTALDH1A1LMNANPC1HTT
SCHEMBL132839 0.72 KMT2A (0.80) MAPTALDH1A1LMNAHPGDKDM4E
SCHEMBL24442034 0.70 TDP1 (0.56) MAPTALDH1A1LMNANPC1HTT
SCHEMBL135797 0.70 MAPT (0.59) MAPTALDH1A1LMNAHPGDKDM4E
SCHEMBL12430193 0.69 ALDH1A1 (0.39) MAPTALDH1A1LMNANPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430029-B1 THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS UNIV LEUVEN KATH (BE) 2018-01-10 EP disclosed
US-9499563-B2 Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2016-11-22 US disclosed
US-20140296272-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS CISTIM LEUVEN VZW (BE) 2014-10-02 US disclosed
US-8785638-B2 Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2014-07-22 US disclosed
US-20120059028-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296272-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS TYMP, DUT, MAVS MAPT 2061/4885ALDH1A1 1925/4885LMNA 3907/4885
US-20120059028-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS TYMP, DUT, MAVS MAPT 2061/4885ALDH1A1 1925/4885LMNA 3907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.